Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Item No. 24863

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide (Item No. 19556) and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.1 C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.2,3 Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.4 It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).5 Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.2,6 As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1932]
WARNING This product is not for human or veterinary use.
1. Role of sulfatide in normal and pathological cells and tissues. J. Lipid Res. 53(8), 1437-1450 (2012).
2. Sulfatide with short fatty acid dominates in astrocytes and neurons. FEBS J. 273(8), 1782-1790 (2006).
3. Distribution of C16:0, C18:0, C24:1, and C24:0 sulfatides in central nervous system lipid rafts by quantitative ultra-
4. Levels of plasma sulfatides C18 : 0 and C24 : 1 correlate with disease status in relapsing-
5. Quantification of plasma sulfatides by mass spectrometry: Utility for metachromatic leukodystrophy. Anal. Chim. Acta 955, 79-85 (2017).
6. Changes in the fatty acid composition of cerebrosides and sulfatides of human nervous tissue with age. J. Lipid Res. 9(2), 215-225 (1968).